{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-455557","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2026-11-10T21:27:44+00:00","discovered_at":"2026-11-10T21:29:00.282953+00:00","generated_at":"2026-11-10T21:29:12.038233+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Biomea Q3 net loss narrows to $6.2M; cash of $26.8M funds runway into Q2 2027","bullets":["Net loss attributable to common stockholders $6.2M vs $16.4M in Q3 2025; nine-month net loss $26.9M vs $66.4M.","R&D expense $8.5M, down $5.9M YoY on lower manufacturing, clinical and headcount costs; G&A $4.4M vs $4.2M.","Cash, cash equivalents and restricted cash $26.8M at Sept 30, 2026; runway projected into Q2 2027.","COVALENT-211 Phase II enrollment complete in insulin-deficient T2D; Week 26 HbA1c topline data expected Q1 2027. COVALENT-212 topline expected Q2 2027.","BMF-650 Phase I: 6.1% (6.2 kg) mean weight loss at Day 29 in Cohort 5; 1.5-3.2% in Cohorts 1-4 vs 0.1% placebo; all TEAEs mild or moderate."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-455557","json":"https://secwatch.observer/filing/0001193125-26-455557.json","markdown":"https://secwatch.observer/filing/0001193125-26-455557.md","text":"https://secwatch.observer/filing/0001193125-26-455557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526455557/0001193125-26-455557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526455557/bmea-20261110.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-10T21:29:12.038233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}